½ÃÀ庸°í¼­
»óǰÄÚµå
1612616

¼¼°èÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå : Á¦Ç°, °Ë»ç ±â¼ú, ¿ëµµ, À¯Åë ä³Î, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Blood Glucose Monitoring Market by Product, Testing Technology, Application, Distribution Channel, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 186 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀº 2023³â¿¡ 130¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 140¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.28%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 228¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ´Â °³ÀÎ, ƯÈ÷ ´ç´¢º´ ȯÀÚÀÇ Æ÷µµ´ç ¼öÁØÀ» ÃøÁ¤Çϰí ÃßÀûÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀåÄ¡¿Í ±â¼ú°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. °Ç°­À» º¸ÀåÇϱâ À§ÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÁÖµÈ ¿ëµµ´Â ´ç´¢º´ ȯÀÚÀÇ °³ÀÎ »ç¿ë, Áø´Ü ¸ñÀûÀÇ ÀÓ»ó ÇöÀå¿¡¼­ÀÇ »ç¿ë, ±×¸®°í Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» À§ÇÑ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áø·á¼Ò, ÀçÅà Äɾî ȯ°æ, °³ÀÎ ¼ÒºñÀÚÀÔ´Ï´Ù. ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ¼¼°èÀÇ ´ç´¢º´ À¯º´·ü »ó½Â, ´ç´¢º´ °ü¸®ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀǽÄÀÇ ³ô¾ÆÁü, ¸ð´ÏÅ͸µ ±â±âÀÇ ±â¼úÀû Áøº¸, Àúħ½À¡¤ºñħ½À ±â±â·ÎÀÇ ½ÃÇÁÆ® µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå °³Ã´ÀÇ ±âȸ·Î¼­´Â ¿ø°Ý ¸ð´ÏÅ͸µ°ú º¸´Ù Á¤È®ÇÑ µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ µðÁöÅÐ Çコ Ç÷§Æû°ú AIÀÇ ÅëÇÕ, ¿þ¾î·¯ºí ±â¼úÀÇ °³¹ß, ´ç´¢º´ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï±¹ ½ÃÀå¿¡¼­ÀÇ È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °í±Þ ¸ð´ÏÅ͸µ ÀåºñÀÇ °í°¡ÀÇ ºñ¿ë, Àú¼Òµæ Áö¿ªÀÇ °Ç°­ °ü¸®¿¡ ´ëÇÑ Á¦ÇÑµÈ Á¢±Ù, ´ç´¢º´ÀÇ Àڱ⠰ü¸®¿¡ ´ëÇÑ Àνİú ±³À°ÀÇ ºÎÁ· µîÀÌ ÀÖ½À´Ï´Ù. ±ä ¼ö¸í ¼¾¼­¿Í µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ °­È­µÈ ¼ÒÇÁÆ®¿þ¾î µî ȯÀÚÀÇ ÆíÀǼº°ú »ç¿ë ÆíÀǼº¿¡ ÁßÁ¡À» µÐ Á¦Ç°À» È®´ëÇÔÀ¸·Î½á Çõ½ÅÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù°í »ý°¢µË´Ï´Ù. ±â¼ú Áøº¸µµ ÇöÀúÇϱ⠶§¹®¿¡ ±âÁ¸ ±â¾÷µµ ½Å±Ô Âü°¡±â¾÷µµ ½ÃÀå Á¡À¯À² ȹµæ¿¡ ¸ÅÁøÇϰí ÀÖ½À´Ï´Ù. °Ç°­ Äɾî Á¦°ø¾÷ü¿ÍÀÇ Çù·Â °ü°è Ãß±¸ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °³º°È­µÈ ´ç´¢º´ °ü¸® ¼Ö·ç¼Ç¿¡ ÁÖ·ÂÇÔÀ¸·Î½á, ±â¾÷Àº °æÀï ¿ìÀ§¼ºÀ» ȹµæÇØ, °³ÀÎ Áß½ÉÀÇ ÇコÄɾ ÇâÇÑ Æ®·»µåÀÇ °íÁ¶¿¡ µû¸¦ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 130¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 140¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 228¾ï ´Þ·¯
CAGR(%) 8.28%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò±â À§ÇØ Áغñ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°Í Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ´ç´¢º´ÀÇ À¯Çà°ú ÀÎÁöµµ Çâ»ó ÇÁ·Î±×·¥
    • ºñħ½ÀÀû ±â¼ú¿¡ÀÇ ±âÈ£ÀÇ °íÁ¶
    • ÀçÅà °³È£ ȯ°æ¿¡ À־ÀÇ Áö¼ÓÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µÀÇ Çʿ伺
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ¸®ÄÝ ¹®Á¦
  • ½ÃÀå ±âȸ
    • Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ µðÀÚÀΰú ±â´ÉÀÇ Áøº¸
    • Ç÷´ç ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ »óȯ °­È­
  • ½ÃÀåÀÇ °úÁ¦
    • Ç÷´ç ¸ð´ÏÅ͸µÀÇ »ý»ê°ú ¿î¿µÀÇ º¹À⼺

Porter's Five Force : Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force ÇÁ·¹ÀÓ¿öÅ©´Â Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Force Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ´ç´¢º´ÀÇ ¸¸¿¬°ú °è¹ß ÇÁ·Î±×·¥ÀÇ °³¼±
      • ºñħ½ÀÀû Ç÷´ç ¸ð´ÏÅ͸µ ±â¼ú¿¡ ´ëÇÑ È£°¨µµ Áõ°¡
      • Áö¼ÓÀûÀÎ ÀçÅà ÄɾîÀÇ Çʿ伺
    • ¾ïÁ¦¿äÀÎ
      • Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ¾Ç¿µÇâÀÇ »ý°¢
    • ±âȸ
      • Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ¼³°è¿Í ±â´ÉÀÇ Áøº¸
      • Ç÷´ç ¸ð´ÏÅ͸µ ȯºÒ °­È­
    • °úÁ¦
      • Ç÷´ç ¸ð´ÏÅ͸µÀÇ Á¦ÀÛ°ú ¿î¿ëÀÇ º¹À⼺
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Á¦Ç° : ÀÚ±â Ç÷´ç ÃøÁ¤±â¿¡¼­ °³º° Áöħ Á¦°ø
    • ½ÃÇè ±â¼ú: ÈÞ´ëÇü¡¤°¡Á¤¿ë ±â±â·Î¼­ °³¹ßµÇ´Â Àü±Ø½Ä Ç÷´ç ¸ð´ÏÅÍÀÇ °¡´É¼º
    • ¿ëµµ: 1Çü ´ç´¢º´ÀÇ Á¤È®¼º°ú Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» °®Ãá °í±Þ CGMÀÇ Çʿ伺
    • ÃÖÁ¾ »ç¿ëÀÚ : º´¿ø¿¡¼­ÀÇ ÀÓ»ó È¿À²°ú ȯÀÚ Ã³¸®·®À» ÃÖÀûÈ­ÇÏ´Â Ç÷´ç ¸ð´ÏÅÍ Á¦°ø
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå : Á¦Ç°º°

  • Áö¼Ó Ç÷´ç ¸ð´ÏÅÍ
    • Àν¶¸° ÆßÇÁ
    • ¼¾¼­
    • ¼Û½Å±â¿Í ¼ö½Å±â
  • ¼¿ÇÁ ¶Ç´Â ÀÏȸ¿ë ¸ð´ÏÅÍ
    • Ç÷´ç ÃøÁ¤±â
    • ·£½Ë
    • °Ë»ç

Á¦7Àå Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå : °Ë»ç ±â¼ú

  • Àü±Ø½Ä Ç÷´ç ¸ð´ÏÅÍ
  • ±¤Àü½Ä Ç÷´ç ¸ð´ÏÅÍ

Á¦8Àå Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå : ¿ëµµº°

  • ÀӽŠ´ç´¢º´
  • 1Çü ´ç´¢º´
  • 2Çü ´ç´¢º´

Á¦9Àå Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå : À¯Åë ä³Îº°

  • ¿ÀÇÁ¶óÀÎ
  • ¿Â¶óÀÎ

Á¦10Àå Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ȨÄɾî
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦11Àå ¾Æ¸Þ¸®Ä« Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Abbott, Bigfoot BiomedicalÀÇ Àμö¸¦ ¿Ï·á
    • Dexcom, Àν¶¸° ¾øÀÌ 2Çü ´ç´¢º´À» °ü¸®ÇÒ ¼ö ÀÖ´Â »õ·Î¿î ¿þ¾î·¯ºíÀ» ¹ßÇ¥
    • Astellas¿Í Roche Diabetes Care Japan, BlueStar¿Í Á¦ÈÞÇØ ÅëÇÕ ´ç´¢º´ Àڱ⠰ü¸® ¼Ö·ç¼ÇÀÇ °³¹ß¡¤»óǰȭ¸¦ À§ÇÑ Á¦ÈÞ °è¾àÀ» ü°á
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • AdvaCare Pharma
  • Advin Health Care
  • ARKRAY, Inc.
  • Ascensia Diabetes Care Holdings AG by PHC Holdings Corporation
  • B. Braun Melsungen AG
  • BAYER AG
  • Becton, Dickinson and Company
  • Dexcom, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlySens Incorporated
  • I-SENS, Inc.
  • Insulet Corporation
  • Johnson & Johnson Services, Inc.
  • LifeScan IP Holding, LLC.
  • Medtronic PLC
  • Medtrum Technologies Inc.
  • Nemaura Medical Inc.
  • Nipro Europe Group Companies
  • Nova Biomedical
  • Novo Nordisk A/s
  • NXP Semiconductors NV
  • PHC Holding Corporation
  • Prodigy Diabetes Care LLC
  • Sanofi SA
  • Senseonics Holdings Inc.
  • Sinocare Inc.
  • Teladoc Health, Inc.
  • Terumo Corporation
  • Ypsomed AG
JHS 24.12.24

The Blood Glucose Monitoring Market was valued at USD 13.06 billion in 2023, expected to reach USD 14.08 billion in 2024, and is projected to grow at a CAGR of 8.28%, to USD 22.80 billion by 2030.

The scope and definition of the blood glucose monitoring market pertain to devices and technologies used to measure and track glucose levels in individuals, particularly those with diabetes. Blood glucose monitoring is crucial for managing diabetes, preventing complications, and ensuring overall health. Applications primarily include personal use by individuals with diabetes, in clinical settings for diagnostic purposes, and increasingly for continuous monitoring. End-users are predominantly hospitals, clinics, home care settings, and individual consumers. Key growth factors driving this market include the rising prevalence of diabetes globally, increased awareness about the benefits of diabetes management, technological advancements in monitoring devices, and a shift towards minimally invasive and non-invasive devices. Emerging opportunities in the market include the integration of digital health platforms and AI for remote monitoring and more accurate data analytics, wearable technology development, and expansion in emerging markets where diabetes cases are on the rise. Limitations and challenges affecting growth include high costs of advanced monitoring devices, limited access to healthcare in low-income regions, and lack of awareness or education about self-management of diabetes. Companies could innovate by investing in research for more cost-effective solutions and expanding offerings that focus on patient convenience and ease of use, including long-lasting sensors and enhanced software for data interpretation. The nature of the market is highly competitive with rapid technological advances, with both established companies and new entrants striving to capture market share. Areas of potential innovation include developing fully non-invasive glucose monitoring technologies, improving accuracy and integration with smartphones and smartwatches, and pursuing collaboration with healthcare providers for improved patient outcomes. Focusing on personalized diabetes management solutions could offer companies a competitive edge and align with the growing trend towards individual-centric healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 13.06 billion
Estimated Year [2024] USD 14.08 billion
Forecast Year [2030] USD 22.80 billion
CAGR (%) 8.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Glucose Monitoring Market

The Blood Glucose Monitoring Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of diabetes and improved awareness programs
    • Increasing preference for non-invasive blood glucose monitoring technology
    • Need for continuous blood glucose monitoring in-home care settings
  • Market Restraints
    • Adverse recalls of blood glucose monitoring systems
  • Market Opportunities
    • Advancements in design and capabilities of blood glucose monitoring systems
    • Enhancements in the reimbursements for blood glucose monitoring
  • Market Challenges
    • Complexity in the production and operation of blood glucose monitoring

Porter's Five Forces: A Strategic Tool for Navigating the Blood Glucose Monitoring Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Glucose Monitoring Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Glucose Monitoring Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Glucose Monitoring Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Glucose Monitoring Market

A detailed market share analysis in the Blood Glucose Monitoring Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Glucose Monitoring Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Glucose Monitoring Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Glucose Monitoring Market

A strategic analysis of the Blood Glucose Monitoring Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Glucose Monitoring Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdvaCare Pharma, Advin Health Care, ARKRAY, Inc., Ascensia Diabetes Care Holdings AG by PHC Holdings Corporation, B. Braun Melsungen AG, BAYER AG, Becton, Dickinson and Company, Dexcom, Inc., F. Hoffmann-La Roche Ltd., GlySens Incorporated, I-SENS, Inc., Insulet Corporation, Johnson & Johnson Services, Inc., LifeScan IP Holding, LLC., Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Nipro Europe Group Companies, Nova Biomedical, Novo Nordisk A/s, NXP Semiconductors N.V., PHC Holding Corporation, Prodigy Diabetes Care LLC, Sanofi S.A., Senseonics Holdings Inc., Sinocare Inc., Teladoc Health, Inc., Terumo Corporation, and Ypsomed AG.

Market Segmentation & Coverage

This research report categorizes the Blood Glucose Monitoring Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Continuous Blood Glucose Monitors and Self or One Time Monitors. The Continuous Blood Glucose Monitors is further studied across Insulin Pumps, Sensors, and Transmitter & Receiver. The Self or One Time Monitors is further studied across Blood Glucose Meter, Lancets, and Testing Strips.
  • Based on Testing Technology, market is studied across Electrode Type Blood Glucose Monitor and Photoelectric Blood Glucose Monitor.
  • Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Home Care and Hospital & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of diabetes and improved awareness programs
      • 5.1.1.2. Increasing preference for non-invasive blood glucose monitoring technology
      • 5.1.1.3. Need for continuous blood glucose monitoring in-home care settings
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of blood glucose monitoring systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in design and capabilities of blood glucose monitoring systems
      • 5.1.3.2. Enhancements in the reimbursements for blood glucose monitoring
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in the production and operation of blood glucose monitoring
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Provision of personalized guidance in self-monitoring blood glucose monitors
    • 5.2.2. Testing Technology: Potential of electrode-type blood glucose monitors to be developed as portable and home-use devices
    • 5.2.3. Application: Need for sophisticated CGMs with accuracy and constant monitoring for type-1 diabetes
    • 5.2.4. End-User: Provision of blood glucose monitors that optimize clinical efficiency and patient throughput in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Glucose Monitoring Market, by Product

  • 6.1. Introduction
  • 6.2. Continuous Blood Glucose Monitors
    • 6.2.1. Insulin Pumps
    • 6.2.2. Sensors
    • 6.2.3. Transmitter & Receiver
  • 6.3. Self or One Time Monitors
    • 6.3.1. Blood Glucose Meter
    • 6.3.2. Lancets
    • 6.3.3. Testing Strips

7. Blood Glucose Monitoring Market, by Testing Technology

  • 7.1. Introduction
  • 7.2. Electrode Type Blood Glucose Monitor
  • 7.3. Photoelectric Blood Glucose Monitor

8. Blood Glucose Monitoring Market, by Application

  • 8.1. Introduction
  • 8.2. Gestational Diabetes
  • 8.3. Type 1 Diabetes
  • 8.4. Type 2 Diabetes

9. Blood Glucose Monitoring Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Blood Glucose Monitoring Market, by End-User

  • 10.1. Introduction
  • 10.2. Home Care
  • 10.3. Hospital & Clinics

11. Americas Blood Glucose Monitoring Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Blood Glucose Monitoring Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Blood Glucose Monitoring Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Abbott Completes Acquisition Of Bigfoot Biomedical
    • 14.3.2. Dexcom Announces Novel Wearable For Managing Type 2 Diabetes - Without Insulin
    • 14.3.3. Astellas and Roche Diabetes Care Japan Ink Partnership Agreement To Develop And Commercialize Integrated Diabetes Self-Management Solution with BlueStar
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AdvaCare Pharma
  • 3. Advin Health Care
  • 4. ARKRAY, Inc.
  • 5. Ascensia Diabetes Care Holdings AG by PHC Holdings Corporation
  • 6. B. Braun Melsungen AG
  • 7. BAYER AG
  • 8. Becton, Dickinson and Company
  • 9. Dexcom, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GlySens Incorporated
  • 12. I-SENS, Inc.
  • 13. Insulet Corporation
  • 14. Johnson & Johnson Services, Inc.
  • 15. LifeScan IP Holding, LLC.
  • 16. Medtronic PLC
  • 17. Medtrum Technologies Inc.
  • 18. Nemaura Medical Inc.
  • 19. Nipro Europe Group Companies
  • 20. Nova Biomedical
  • 21. Novo Nordisk A/s
  • 22. NXP Semiconductors N.V.
  • 23. PHC Holding Corporation
  • 24. Prodigy Diabetes Care LLC
  • 25. Sanofi S.A.
  • 26. Senseonics Holdings Inc.
  • 27. Sinocare Inc.
  • 28. Teladoc Health, Inc.
  • 29. Terumo Corporation
  • 30. Ypsomed AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦